So you just got a BTD for your top drug? Don't be surprised to see the enthusiasm fizzle fast among investors
We’ve already seen studies spotlighting how the FDA’s breakthrough therapy designation can lead doctors and patients to get unreasonably pumped about a drug — even though …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
